InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
64,022.41
(
1.80%
)
Post# of 251706
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119567
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jcrty post# 242772

Thursday, 06/09/2022 11:53:59 AM

Thursday, June 09, 2022 11:53:59 AM

Post# of 251706
Re: ENTA Jefferies webcast /EDP-235 data release

I actually prefer a July (rather than June) release of the EDP-235 phase-1 data since this presumably means that ENTA will release the data from all eight dosing cohorts (5 SAD + 3 MAD) rather than just some of the cohorts (https://www.clinicaltrials.gov/ct2/show/NCT05246878 ).

Had ENTA released only partial data from this trial, investors would’ve been left wondering if there might be a safety issue at one of the (higher-dose) cohorts yet to be reported.

Regarding the partnership discussion on the webcast, I would take the comments by ENTA’s executive (Tara Lynn Kieffe, SVP) with a grain of salt. If the phase-1 data are positive, ENTA will almost certainly attempt to partner EDP-235 as soon as possible.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up